Pilot Feasibility Trial of the SafeLM Supraglottic Airway (SGA)

Description

The purpose of this study is to assess the feasibility of SafeLM as a primary airway device and as a conduit for intubation with and without the use of a bougie

Conditions

Anesthesia

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to assess the feasibility of SafeLM as a primary airway device and as a conduit for intubation with and without the use of a bougie

Pilot Feasibility Trial of the SafeLM Supraglottic Airway

Pilot Feasibility Trial of the SafeLM Supraglottic Airway (SGA)

Condition
Anesthesia
Intervention / Treatment

-

Contacts and Locations

Houston

The University of Texas Health Science Center at Houston, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * elective surgery requiring general anesthesia and airway management using a supraglottic airway device or endotracheal intubation
  • * pregnancy
  • * known or suspected difficult airway management
  • * history of oropharyngeal or upper airway surgery
  • * known or suspected airway or respiratory pathology, such as significant obstructive sleep apnea or chronic obstructive pulmonary disease (COPD)
  • * BMI greater than 40 kg/m2
  • * unable to undergo intubation via the oral route
  • * known or suspected full stomach or other risk factors for aspiration
  • * contraindication for the use of neuromuscular blocking agents
  • * history of significant gastroesophageal reflux disease (GERD)
  • * Vulnerable populations (cognitively impaired persons, prisoners)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

The University of Texas Health Science Center, Houston,

Lauren M Nakazawa, MD, PRINCIPAL_INVESTIGATOR, The University of Texas Health Science Center, Houston

Study Record Dates

2024-12-02